Sanjay Mathew
Vice Chair for Research at Baylor College of Medicine
Data updated
Research Footprint
Sanjay Mathew appears in 27 tracked papers (2012–2026), most studied alongside Ketamine, Placebo and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (1200 citations).
Frequent co-authors: James Murrough, Daniel Iosifescu and Brittany O'Brien.
Publication Landscape
How the 27 papers Blossom tracks for Sanjay Mathew line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Sanjay Mathew's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 27 of 27 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Sanjay Mathew publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Sanjay Mathew publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dr. Sanjay Mathew directs the Mood and Anxiety Disorders Program at Baylor College of Medicine. His research program is dedicated to discovering novel pharmacotherapies for difficult-to-treat depression and PTSD, with a primary focus on the rapid-acting effects of ketamine. He has significantly contributed to the literature on the pathophysiology of anxiety and the clinical management of treatment-resistant patients.
Key Impact
Leading expert in experimental therapeutics for treatment-resistant mood and anxiety disorders.
Collaboration Network
36 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Sanjay Mathew's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Sanjay Mathew is associated with.
Baylor College of Medicine
Academic medical center in Houston affiliated with multiple Texas Medical Center hospitals. Conducts psilocybin and MDMA clinical trials for veteran PTSD in partnership with the Michael E. DeBakey VA, and houses the ELIPSIS program — a dedicated initiative on the ethical and legal implications of psychedelics in society.
View stakeholder →Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai in New York hosts the Parsons Research Center for Psychedelic Healing, founded by Rachel Yehuda, a psychiatrist known for three decades of work on PTSD and the biology of trauma. The centre grew out of a 2021 gift from the Bob and Renee Parsons Foundation and was expanded and renamed in 2024 with further funding and a purpose-built facility in Upper Manhattan. Working closely with the James J. Peters VA Medical Center in the Bronx, its researchers test MDMA-assisted therapy for veterans with PTSD and psilocybin for civilians, and are developing protocols for delivering MDMA within group psychotherapy. The programme pairs clinical trials with training designed to prepare therapists for supervised psychedelic-assisted care.
View stakeholder →Mount Sinai
hospitalThe Center for Psychedelic Psychotherapy and Trauma Research located at Mount Sinai and the James J. Peters Department of Veterans Affairs examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms. The Parsons Research Center for Psychedelic Healing has also recently opened at the Icahn School of Medicine at Mount Sinai.
View stakeholder →